| Date Initiated by Firm | June 04, 2026 |
| Date Posted | July 09, 2026 |
| Recall Status1 |
Open3, Classified |
| Recall Number | Z-2715-2026 |
| Recall Event ID |
99213 |
| Product Classification |
System, test, automated, antimicrobial susceptibility, short incubation - Product Code LON
|
| Product | VITEK 2 AST-N447 TEST KIT
Product reference 424620 |
| Code Information |
Lot 0853293604
UDI-DI 03573026634551
Product is not registered in the US. OUS only. |
| FEI Number |
1950204
|
Recalling Firm/ Manufacturer |
Biomerieux Inc 595 Anglum Rd Hazelwood MO 63042-2320
|
| For Additional Information Contact | bioMerieux Customer Service Center 314-731-8526 |
Manufacturer Reason for Recall | Potential for false resistant carbapenem and/or cephalosporin results when analyzing samples with kits from affected lot that have pouch foil fractures. |
FDA Determined Cause 2 | Process change control |
| Action | Firm began notifying customers on June 4, 2026.
Customers are instructed to dispose of pouches from the affected lot (Ref 424620, Lot 0853293604). Customer may choose to inspect each pouch in their inventory and only dispose of those with "P7" on the label, or they may choose to dispose of all cards from Lot 0853293604 in their inventory.
Based on individual customer policy, customers may wish to perform retrospective review of resistant results.
Customers should distribute the information to all appropriate personnel in their laboratory. If product was transferred or further distributed, customer should notify downstream users/accounts. |
| Quantity in Commerce | 45,900 cards |
| Distribution | International distribution to the countries of Belgium and the Netherlands. |
| Total Product Life Cycle | TPLC Device Report |
|
1 A record in this database is created when a firm initiates a correction or removal action. The record is updated if the FDA identifies a violation and classifies the action as a recall, and it is updated for a final time when the recall is terminated. Learn more about medical device recalls. 2 Per FDA policy, recall cause determinations are subject to modification up to the point of termination of the recall. 3 The manufacturer has initiated the recall and not all products have been corrected or removed. This record will be updated as the status changes.
|